Nielsen KK - Search Results

1

The influence of conformational restriction in the C-terminus of growth hormone secretagogues on their potency.

Peschke B, Ankersen M, Bauer M, Hansen TK, Hansen BS, Nielsen KK, Raun K, Richter L, Westergaard L. Peschke B, et al. Among authors: nielsen kk. Eur J Med Chem. 2002 Jun;37(6):487-501. doi: 10.1016/s0223-5234(02)01370-3. Eur J Med Chem. 2002. PMID: 12204475

2

A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.

Ankersen M, Johansen NL, Madsen K, Hansen BS, Raun K, Nielsen KK, Thogersen H, Hansen TK, Peschke B, Lau J, Lundt BF, Andersen PH. Ankersen M, et al. Among authors: nielsen kk. J Med Chem. 1998 Sep 10;41(19):3699-704. doi: 10.1021/jm9801962. J Med Chem. 1998. PMID: 9733495

3

Novel orally active growth hormone secretagogues.

Hansen TK, Ankersen M, Hansen BS, Raun K, Nielsen KK, Lau J, Peschke B, Lundt BF, Thøgersen H, Johansen NL, Madsen K, Andersen PH. Hansen TK, et al. Among authors: nielsen kk. J Med Chem. 1998 Sep 10;41(19):3705-14. doi: 10.1021/jm980197u. J Med Chem. 1998. PMID: 9733496

4

Pharmacological characterisation of a new oral GH secretagogue, NN703.

Hansen BS, Raun K, Nielsen KK, Johansen PB, Hansen TK, Peschke B, Lau J, Andersen PH, Ankersen M. Hansen BS, et al. Among authors: nielsen kk. Eur J Endocrinol. 1999 Aug;141(2):180-9. doi: 10.1530/eje.0.1410180. Eur J Endocrinol. 1999. PMID: 10427162

5

New highly potent dipeptidic growth hormone secretagogues with low molecular weight.

Peschke B, Ankersen M, Hansen TK, Hansen BS, Lau J, Nielsen KK, Raun K. Peschke B, et al. Among authors: nielsen kk. Eur J Med Chem. 2000 Jun;35(6):599-618. doi: 10.1016/s0223-5234(00)00160-4. Eur J Med Chem. 2000. PMID: 10906412

6

Absorption and systemic availability of two synthetic growth hormone secretogogues and transport of glucose by the proximal small intestine of anestrus dogs after administering estradiol.

Nielsen KK, Buddington KK, Raun K, Hansen TK, Buddington RK. Nielsen KK, et al. J Comp Physiol B. 2003 Feb;173(1):61-7. doi: 10.1007/s00360-002-0312-x. Epub 2003 Jan 9. J Comp Physiol B. 2003. PMID: 12592444

7

Synthesis, properties and prodrug potential of 2-methyl-2-oxy- and 2-methyl-2-thio-4H-1,3-benzodioxin-4-ones.

Ankersen M, Nielsen KK, Senning A. Ankersen M, et al. Among authors: nielsen kk. Acta Chem Scand (Cph). 1989 Mar;43(3):213-21. doi: 10.3891/acta.chem.scand.43-0213. Acta Chem Scand (Cph). 1989. PMID: 2486131 Review.

8

Aspirin prodrugs: synthesis of 2-substituted 2-methyl-4H-1,3-benzodioxin-4-ones and their screening for prodrug potential.

Nielsen KK, Senning A. Nielsen KK, et al. Acta Chem Scand (Cph). 1990 Oct;44(9):952-6. doi: 10.3891/acta.chem.scand.44-0952. Acta Chem Scand (Cph). 1990. PMID: 2291862

9

Determination of ragaglitazar, a novel dual acting peroxisome proliferator-activated receptor (PPAR) alpha and -gamma agonist, in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry.

Andersen MP, Nielsen KK. Andersen MP, et al. Among authors: nielsen kk. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 May 5;788(1):45-55. doi: 10.1016/s1570-0232(02)01014-0. J Chromatogr B Analyt Technol Biomed Life Sci. 2003. PMID: 12668070

10

Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes.

Skrumsager BK, Nielsen KK, Müller M, Pabst G, Drake PG, Edsberg B. Skrumsager BK, et al. Among authors: nielsen kk. J Clin Pharmacol. 2003 Nov;43(11):1244-56. doi: 10.1177/0091270003257230. J Clin Pharmacol. 2003. PMID: 14551179 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

158 results

Search Page